Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuazo, Miren, Arasanz, Hugo, Fernández‐Hinojal, Gonzalo, García‐Granda, Maria Jesus, Gato, María, Bocanegra, Ana, Martínez, Maite, Hernández, Berta, Teijeira, Lucía, Morilla, Idoia, Lecumberri, Maria Jose, Fernández de Lascoiti, Angela, Vera, Ruth, Kochan, Grazyna, Escors, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609910/
https://www.ncbi.nlm.nih.gov/pubmed/31273938
http://dx.doi.org/10.15252/emmm.201910293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609910/
https://www.ncbi.nlm.nih.gov/pubmed/31273938
http://dx.doi.org/10.15252/emmm.201910293

Ejemplares similares